Needham Initiates Coverage On Immix Biopharma with Buy Rating, Announces Price Target of $21

Benzinga · 3d ago
Needham analyst Gil Blum initiates coverage on Immix Biopharma (NASDAQ:IMMX) with a Buy rating and announces Price Target of $21.